#Canada #Pain Management #Saskatoon #ZYUS Life Sciences #Trichomylin

ZYUS Life Sciences Expands Pain Management Patent Portfolio

On May 5, 2026, ZYUS Life Sciences Corporation, a clinical-stage life sciences company, announced the issuance of its second U.S. patent focused on pain management. The new patent, titled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT, was granted by the United States Patent and Trademark Office (USPTO). This important development reinforces ZYUS's position in the evolving field of non-opioid pain therapies.

Background of the Patent Application

The new patent stems from International Patent Application No. PCT/CA2021/050430 and marks a significant milestone in ZYUS's commitment to innovating within the pain management sector. The patent covers a unique, non-intoxicating formulation that utilizes cannabichromene (CBC) as part of an approach to manage pain effectively.

ZYUS's first U.S. patent supports its lead drug candidate, Trichomylin® softgel capsules, which consists of a proprietary blend of cannabinoids designed to treat various kinds of pain. The latest addition to the patent portfolio aligns with their expanding pipeline of non-opioid therapies aimed at addressing chronic and neuropathic pain conditions.

Significance for Clinical Research

This second patent further validates ZYUS's efforts in advancing their clinical studies centered around neuropathic pain, including specific conditions such as diabetic and cancer-related neuropathies. These areas are vital for many patients suffering from debilitating pain conditions, and the ongoing research reflects ZYUS's dedicated approach to improving pain management.

The issuance of this patent not only strengthens ZYUS's intellectual property portfolio but also enhances the chances of successful Investigational New Drug (IND) submissions. With IND-enabling studies completed, ZYUS is in a strong position to initiate clinical trials in the U.S. This step is critical in moving towards regulatory approval and eventual market introduction of their novel therapies.

Company Insights and Future Directions

Brent Zettl, President and CEO of ZYUS, emphasized the importance of the new patent, stating, "The issuance of this U.S. patent further validates our commitment to advancing a differentiated portfolio of novel non-opioid pain drugs. We remain focused on developing innovative treatment options to address significant unmet needs in chronic and neuropathic pain."

ZYUS Life Sciences Corporation, traded on the TSX Venture Exchange under the ticker symbol ZYUS, focuses on developing and commercializing cannabinoid-based pharmaceutical drug candidates. This strategic direction is driven by a rigorous pursuit of scientific research and clinical exploration, ensuring adequate intellectual property coverage for its innovative therapies.

The company aims to transform pain management by providing viable alternatives to existing opioid-based solutions, thereby addressing the urgent need for safer pain relief options.

Further information about ZYUS Life Sciences Corporation and its advancements in cannabinoid-based pain management products can be accessed through their website at www.zyus.com or by following them on social media platforms.

Conclusion

As ZYUS continues to pioneer innovative drug candidates for pain management, this recent patent issuance could significantly impact the landscape of pain relief solutions. The commitment to developing non-opioid treatments demonstrates a promising shift towards safer therapeutic options for those suffering from chronic and neuropathic pain.